Abemaciclib, aromatase inhibitor, Eli Lilly and Company, endocrine therapy, Tamoxifen, Verzenio
Abemaciclib with endocrine therapy is approved by FDA in HER 2 positive breast cancer
March 2023: Abemaciclib (Verzenio, Eli Lilly and Company) and endocrine therapy (tamoxifen or an aromatase inhibitor) have been approved by the Food and Drug Administration (FDA) for the adjuvant treatment of adult patients with ..
Eli Lilly and Company, FDA, Food and Drug Administration, Jaypirca, Mantle cell lymphoma, MCL, pirtobrutinib
Accelerated approval is granted by FDA to pirtobrutinib for relapsed or refractory mantle cell lymphoma
Feb 2023: Accelerated approval is granted by FDA to pirtobrutinib (Jaypirca, Eli Lilly and Company) for relapsed or refractory mantle cell lymphoma. In BRUIN (NCT03740529), an open-label, multicenter, single-arm trial of pirtobr..
Eli Lilly and Company, LIBRETTO-001, NCT03157128, RET fusion-positive tumors, Retevmo
Selpercatinib is approved by FDA for locally advanced or metastatic RET fusion-positive solid tumors
November 2022: Selpercatinib (Retevmo, Eli Lilly and Company) received accelerated approval from the Food and Drug Administration to treat adult patients with RET-fused solid tumours that are locally or metastatically advanced, ha..
Abemaciclib, Agilent, Dako Omnis, Eli Lilly and Company, endocrine therapy, Tamoxifen, Verzenio
Abemaciclib is approved by FDA with endocrine therapy for early breast cancer
October 2021: The Food and Drug Administration has approved abemaciclib (Verzenio, Eli Lilly and Company) in combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for adjuvant treatment of adult patients with ho..